IBD Awareness Month: Receive a free bottle of Exhale with any CurQD® Protocol using code IBDEX25 by May 31st.

Evinature Blog

single-img-sidebar

Get your tailored plan today!

Evinature Showcases Groundbreaking CurQD Data at Digestive Disease Week 2025

The DDW Conference: 

Digestive Disease Week 2025 hosts all sorts of medical professionals and researchers from every corner of gastroenterology and the world. The biggest USA-based GI conference, Evinature co-founders showed off CurQD® to hundreds of fascinated GI experts, spellbound pharmaceutical companies, and biotech enthusiasts alike with two posters displaying the latest and greatest CurQD® have to offer.

curqd-ddw-conference

Held from May 3rd to 6th in sunny San Diego, Evinature’s presence is an exciting maneuver that positions CurQD® not just as the famed science-backed nutraceuticals they are, but an answer to insurance companies and patient co-pays alike.  

Poster 1: Cost-Effectiveness of CurQD® for Ulcerative Colitis

A recent study co-conducted by Professor Henit Yanai (Rabin Medical Center, Israel) and Dr. David Rubin (University of Chicago) investigated the cost-benefit analysis of using CurQD® to treat ulcerative colitis, both as an additive to existing treatment and on its own. This study determined that CurQD®, as a nutraceutical novel therapy, was a fraction of the cost of advanced therapies that have already received FDA-approval. The best part: CurQD® doesn’t even need to be FDA approved in order to reach patients, while maintaining the highest quality third-party testing available to market. 

nir-salomon-ddw-cost-benefit-ibd-curqd-treatment

Poster 2: Retrospective Crohn’s Disease Study 

In a presentation that was given earlier this year, Co-Founders Nir Salomon and Professor Shomron Ben-Horin displayed a clinical study wherein mild-to-moderate Crohn’s Disease patients took CurQD® and were monitored before, during and after treatment induction, with results testifying to the restorative potential of CurQD® in such medical cases. This presentation made a round at DDW this year as well, with high levels of success not seen in classic Crohn’s Disease studies or treatments until now. These findings confirm that CurQD® is effective not only for induction of remission in Crohn’s disease but also for maintenance, with real-world durability and low side-effect incidence.

crohn's-study
credit: Aaron Blocker, IBD Patient Advocate (@aaronblocker_)

Behind the Scenes: 

Conferences aren’t just a crossroads for researchers, but the businessmen who put their money where their mouth is to invest real, science-backed solutions. DDW provided a tangible space for our Co-Founders to meet and hold productive conversations with high-ranking pharma reps, prominent gastroenterology science leaders and GI groups. These engagements reinforced CurQD®’s growing reputation as a clinically proven, economically viable nutraceutical protocol for IBD treatment while showing off its cost-benefit potential to help patients save and make gut healthcare affordable. 

shomron-ben-horin-nir-salomon-evinature-ddw

Looking Ahead: 

Our presence at DDW 2025 marks a pivotal moment in Evinature’s journey—underscoring our commitment to scientific excellence and our mission to deliver accessible, effective treatments for patients with Ulcerative Colitis and Crohn’s Disease.

Stay tuned for further updates as we continue to expand CurQD®’s reach through clinical partnerships and global recognition.

Summer-Pitocchelli-Schwartzman
Summer Pitocchelli-Schwartzman

author

Summer Pitocchelli-Schwartzman

single-img-sidebar

Get your tailored plan today!

For the best results it’s important to get the right dosage and combination for your specific needs

Take Assessment